A Phase 1/2, Placebo Controlled Randomized Observer Blind Dose Finding First in Humans Study to Describe the Safety Tolerability and Immunogenicity of an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Healthy Older Adults